Nature communications, 2018-11, Vol.9 (1), p.4664-5, Article 4664
2018
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Titel
- Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer
- Ist Teil von
- Nature communications, 2018-11, Vol.9 (1), p.4664-5, Article 4664
- Ort / Verlag
- England: Nature Publishing Group
- Erscheinungsjahr
- 2018
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- PD-L1 immunohistochemistry correlates only moderately with patient survival and response to PD-(L)1 treatment. Heterogeneity of tumor PD-L1 expression might limit the predictive value of small biopsies. Here we show that tumor PD-L1 and PD-1 expression can be quantified non-invasively using PET-CT in patients with non-small-cell lung cancer. Whole body PD-(L)1 PET-CT reveals significant tumor tracer uptake heterogeneity both between patients, as well as within patients between different tumor lesions.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 2041-1723eISSN: 2041-1723DOI: 10.1038/s41467-018-07131-yTitel-ID: cdi_doaj_primary_oai_doaj_org_article_d775b429652c43478095f6b7bc6015c1
- Format
- –
- Schlagworte
- B7-H1 Antigen - metabolism, Cancer, Carcinoma, Non-Small-Cell Lung - diagnostic imaging, Carcinoma, Non-Small-Cell Lung - drug therapy, Heterogeneity, Humans, Immunohistochemistry, Lesions, Lung cancer, Lung Neoplasms - diagnostic imaging, Lung Neoplasms - drug therapy, Nivolumab - pharmacokinetics, Patients, PD-1 protein, PD-L1 protein, Positron emission, Positron emission tomography, Programmed Cell Death 1 Receptor - metabolism, Radiopharmaceuticals - pharmacokinetics, Tissue Distribution, Tomography, Treatment Outcome, Tumors, Whole Body Imaging